General Counsel and Corporate Secretary · Contineum Therapeutics, Inc. (CTNM)

John Healy

FY2024 is the first fiscal year CompBrief holds for John Healy as a named executive officer of Contineum Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,562,489

Salary $254,683Stock awards $0

2nd of 3 named executive officers at Contineum Therapeutics by FY2024 total.

3 named officers on file for Contineum Therapeutics, FY2024

John Healy’s pay file — $29

  • 1 fiscal year of pay, line by line

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Contineum Therapeutics’s whole pay program stands against its peers

  • Contineum Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTNM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get John Healy’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Healy compensation by year

Contineum Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Contineum Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$254,683
Bonus$0
Stock awards$0
Option awards$2,131,552
Non-equity incentive$123,671
Pension and deferred compensation$0
All other$52,582
Total$2,562,489

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Contineum Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001437749-25-013528, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Contineum Therapeutics, Inc. filed document, accession 0001437749-25-013528. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
Option160,000—$15.73

Per the Outstanding Equity Awards at Fiscal Year-End table in Contineum Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Contineum Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Carmine StengonePresident and Chief Executive Officer$4,900,039
John Healy · this pageGeneral Counsel and Corporate Secretary$2,562,489
Stephen HuhnFormer Chief Medical Officer and Senior Vice President of Clinical Development$2,121,674

The full Contineum Therapeutics compensation record

free company brief

This page is one person within Contineum Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Contineum Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Healy's compensation dossier · One-time report. No refunds.